Answers are grounded in this paper and cite their sources.
Patients with hepatic steatosis are highly susceptible to ischemia-reperfusion injury (IRI) but lack effective therapies. We identify elevated cell-free DNA (cfDNA) as a pathogenic driver and a therapeutic target. In metabolic dysfunction-associated steatotic liver disease (MASLD) patients and rat models, cfDNA levels correlate with IRI severity. Mechanistically, cfDNA acts as a damage-associated molecular pattern (DAMP) that activates endosomal TLR9-MyD88 and cytosolic cGAS-STING signaling cascades. These two pathways cooperatively promote M1 macrophage polarization and amplify the inflammatory response in steatotic liver IRI. To address this, we developed a biomimetic and theranostic approach: TLR9-overexpressing red blood cell membrane-biomimetic ultrasound microbubbles (RBC-MBs). These RBC-MBs mimic the natural cfDNA-scavenging function of erythrocytes, leading to efficient cfDNA adsorption, simultaneous suppression of both TLR9-MyD88 and cGAS-STING pathways, and re-polarization of macrophages to a protective M2 phenotype, thereby blocking the inflammatory cascade. This significantly alleviates hepatic IRI in MASLD rats while enabling concurrent ultrasound imaging. Our findings establish a novel translatable theranostic strategy that leverages a natural cfDNA clearance mechanism to treat steatotic liver IRI.
No takes yet. Share an insight, caveat, or question.
Du et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: